Viking Therapeutics Stock Surges on VK2735 Trial Success

Viking Therapeutics stock closed at $34.34, up 11.44%, fueled by VK2735 Phase 2 success. The trial delivered 14.7% average weight reduction, challenging GLP-1 leaders like Ozempic. Acquisition speculation boosts investor interest.

Shares of Viking Therapeutics, a clinical-stage biotechnology firm, rallied significantly, closing at $34.34 with an 11.44% gain. Investors showed renewed enthusiasm from strong clinical trial data and acquisition rumors by big pharma.

VK2735 Phase 2 VENTURE Trial Results

The key driver was positive data from VK2735, Viking's obesity drug candidate. In the Phase 2 VENTURE study, participants achieved an average 14.7% weight reduction.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

This positions VK2735 as a strong rival in the obesity treatment market, dominated by GLP-1 therapies like Ozempic and Wegovy.

Source Information

Originally published by Ad Hoc News.Read the original article →

Keep exploring

Same topic: VK2735

All VK2735 articles →

Pharmaceutical Manufacturing & Innovation

Wegovy & Mounjaro Boom Fuels Peptide Production Surge for GLP-1 Drugs

The unprecedented demand for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound is triggering a significant global expansion in peptide manufacturing. Learn how key players are investing billions to meet the surging need for these life-changing therapies.

7 min read

Obesity & Metabolic Health

Novo Nordisk Stock Erases Wegovy Gains After CagriSema Miss

Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.

5 min read

Obesity Medications

Viking Therapeutics Shares Surge 12% as Novo's CagriSema Stumbles

Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.

5 min read

More in Medical Research

Medical Research

Tirzepatide vs. Semaglutide: A Comprehensive Guide to Cost and Health Outcomes

A new lifetime economic analysis suggests tirzepatide may offer superior long-term value and clinical outcomes compared to semaglutide for obesity management.

2 min read

Medical Research

The Next Ozempic: A 4-in-1 Breakthrough for Lasting Weight Loss

While Ozempic and similar GLP-1 agonists have revolutionized weight management, new research from Tufts University is exploring a novel 4-in-1 peptide that targets four hormone receptors for potentially greater efficacy and fewer side effects, moving closer to the gold standard of bariatric surgery.

6 min read

Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read